Back to News
Market Impact: 0.32

Canaccord cuts Sangoma stock rating on weak results, pricing pressure

NVDASANGSMCIAPP
Analyst InsightsCompany FundamentalsCorporate EarningsCorporate Guidance & OutlookM&A & RestructuringGeopolitics & War
Canaccord cuts Sangoma stock rating on weak results, pricing pressure

Canaccord downgraded Sangoma Technologies to Hold from Speculative Buy and cut its price target to $4.00 from $9.00 after Q3 results showed revenue, gross margin, and EBITDA all below expectations. LTM revenue fell 8.9% year over year to $219.7 million, with pricing pressure and geopolitical headwinds weighing on smaller UCaaS and CPaaS offerings. Management also reduced fiscal 2026 guidance and launched a strategic review, though infrastructure solutions and voice/SIP trunking showed relative strength.

Analysis

SANG looks less like a simple multiple reset and more like a forced re-rating of the legacy UCaaS/CPaaS model as commoditization outruns customer acquisition leverage. The key second-order issue is mix: larger bundled deployments can improve lifetime value, but they also lengthen cash conversion and make near-term revenue optics look worse right when the market is demanding proof of stabilization. That creates a classic value trap setup unless management can show bookings inflecting before the strategic review drags on. The better relative read-through is not to the broader AI complex but to niche telecom infra and adjacent MSP exposure. Infrastructure revenue holding up suggests buyers are prioritizing mission-critical, sticky spend over point solutions, which should pressure smaller pure-play software vendors with weak differentiation while supporting vendors with higher switching costs and deeper integrations. If pricing pressure is intensifying in commoditized offerings, expect gross margin dispersion to widen across the space over the next 2-3 quarters. The strategic review is a potential catalyst, but it cuts both ways: it can surface private equity interest if the business stabilizes, yet it also signals limited organic confidence and may keep the stock discounted until there is hard evidence of a buyer or asset sale. The contrarian view is that the market may be over-penalizing current results if free cash flow remains positive and the larger-deal pipeline converts; however, with guidance reset, the burden of proof shifts to the next one or two quarters. Absent a clear backlog-to-revenue conversion inflection, downside likely persists over a 1-6 month horizon.